The Summit
25th - 27th October 2010
Summit Venue
The Fairmont Turnberry Isle Resort & Club, Miami
The Next Generation Pharmaceutical Summit has grown to become the standard for senior level pharmaceutical executives looking to share ideas with peers, build partnerships with industry thought leaders, and hear from key experts on how to address some of their most pressing challenges in discovery and development, clinical research and beyond.
White Papers
Crown Bioscience - Biology Expertise
Unlike any other CRO in the industry, Crown Bioscience was founded with the specific aim of building the resources needed to provide more clinically relevant data enabling Phase 0/Phase 1 studies in the preclinical stage of drug development.
Covance: Strategic Outsourcing Partnerships - Innovative Solutions for Improving R&D Productivity in the Biopharmaceutical Industry
Eli Lilly’s August 2008 announcement to transfer an early drug development facility to Covance - in addition to more than 240 Lilly employees and a 10-year service contract - signaled the emergence of a new partnership model between CROs and sponsors. The historic deal piqued the interest of R&D executives across the pharmaceutical industry looking for solutions to address their specific needs. This paper outlines some of the innovative solutions designed to help biopharmaceutical companies reduce fixed costs and improve R&D efficiencies through strategic partnership.
Maxim IC: Power through simplicity
Fairbridge Technologies is a leading supplier and solution provider of the most advanced software available in the cold-chain monitoring industry today. We supply cold-chain visibility solutions for monitoring and tracking of temperature and humidity sensitive products throughout the global supply chain, offering our customers realistic and measurable data to fine-tune processes and gain better control over a product cold chain life cycle.
BD Biosciences: Systematic Excellence
Integrated solutions from BD
BD Biosciences: The Future of Multicolor Flow Cytometry: A 21st Century View
By Vernon C. Maino, Smita Ghanekar, Laurel Nomura, and Robert Balderas, BD Biosciences, San Jose, CA
Acurian: Predictive Modeling in Clinical Trial Enrollment
Archimedes: Clinical Trial Simulation
The intent of this project was to calculate the expected event rate in a control population of patients at risk for a Major Adverse Cardiac Event (MACE). This information was used to inform enrollment in a clinical trial evaluating a candidate compound targeting a novel cardiovascular biomarker.
Archimedes: Portfolio Prioritization
The project objective was to identify which candidate drug, among six in the customer’s clinical development pipeline, would offer the greatest long-term health outcomes and costs benefits.
Source: www.ngpsummit.com© 2010 GDS International Ltd. All rights reserved.